spironolactone has been researched along with Myocardial Infarction in 215 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a sub-study of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS trial), BNP and BigET-1 were measured at baseline and at 1month in 476 patients." | 9.24 | Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac ( Bramlage, P; Fay, R; Girerd, N; Ketelslegers, JM; Michel, JB; Olivier, A; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2017) |
| " The investigation involved 6632 patients of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study." | 9.19 | Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s ( Challande, P; Fay, R; Lacolley, P; Lagrange, J; Pitt, B; Pizard, A; Regnault, V; Rossignol, P; Safar, ME; Zannad, F, 2014) |
| "EPHESUS was a multicentre, double-blind clinical trial in which 6632 patients with acute myocardial infarction (AMI) complicated by LV systolic dysfunction (LVSD) were randomized to receive eplerenone (n = 3319) or placebo (n = 3313)." | 9.19 | Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial. ( Adlam, D; Fay, R; Gunn, J; Iqbal, J; Parviz, Y; Pitt, B; Squire, I; Zannad, F, 2014) |
| "We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset." | 9.19 | Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. ( Flather, M; Hamm, CW; Lopez de Sa, E; Montalescot, G; Orri, M; Pitt, B; Shi, H; Turgonyi, E; Verheugt, F; Vincent, J; Zannad, F, 2014) |
| "The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI)." | 9.17 | Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction? ( Alihanoglu, Y; Bacaksiz, A; Demir, K; Gul, EE; Kayrak, M; Koc, F; Ozdemir, K; Sonmez, O; Tasal, A; Turfan, M; Vatankulu, MA; Yazici, M, 2013) |
| "We evaluated the effect of the selective mineralocorticoid receptor antagonist eplerenone on renal function and the interaction between changes in renal function and subsequent cardiovascular outcomes in patients with heart failure and left ventricular systolic dysfunction after an acute myocardial infarction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 9.16 | Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. ( Bhandari, S; Cleland, JG; Dobre, D; Fay, R; Gustafsson, F; Lamiral, Z; Pitt, B; Rossignol, P; Tala, S; Zannad, F, 2012) |
| "To evaluate the effects of spironolactone on cardiac sympathetic nerve activity (CSNA) and left ventricular (LV) remodelling in patients with ST-segment elevation myocardial infarction (STEMI)." | 9.15 | Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Minami, K; Sato, Y; Sumino, H; Takayama, Y; Toyama, T, 2011) |
| "We evaluated 12-month cost utilization data from 1516 heart failure outpatients enrolled in the Quality-of-Life Substudy of the Eplerenone Post-Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 9.14 | Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). ( Chan, PS; Jones, PG; Nallamothu, BK; Soto, G; Spertus, JA; Weintraub, WS; Zhang, Z, 2009) |
| "In a substudy of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), which evaluated the effects of the selective aldosterone receptor antagonist eplerenone versus placebo, serum levels of collagen biomarkers were measured in 476 patients with congestive heart failure after acute myocardial infarction complicated with left ventricular systolic dysfunction." | 9.14 | Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP ( Angioi, M; Fay, R; Iraqi, W; Ketelslegers, JM; Nuée, J; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2009) |
| "To test the hypothesis that an earlier post-acute myocardial infarction (AMI) eplerenone initiation in patients with left ventricular systolic dysfunction (LVSD) and heart failure (HF) is associated with better long-term outcomes." | 9.14 | Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. ( Adamopoulos, C; Ahmed, A; Angioi, M; Fay, R; Filippatos, G; Pitt, B; Vincent, J; Zannad, F, 2009) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN)." | 9.13 | History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. ( Ahmed, A; Aschermann, M; Cardoso, JS; Corbalán, R; Krum, H; Love, TE; Nicolau, J; Parkhomenko, A; Pitt, B; Shi, H; Solomon, H; Zannad, F, 2008) |
| "Hospitalized patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction (left ventricular ejection fraction < or =40%) treated with standard therapy were randomized 3 to 14 days after the acute myocardial infarction to additional treatment with eplerenone (25 to 50 mg/d; n=3319) or placebo (n=3313)." | 9.13 | Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). ( Bakris, G; DiCarlo, L; Mukherjee, R; Pitt, B; Ruilope, LM, 2008) |
| "The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) randomized clinical trial demonstrated the efficacy of eplerenone, a new aldosterone antagonist diuretic, with standard treatment versus standard treatment alone in the reduction of cardiovascular mortality and cardiovascular-related hospital readmissions for patients with heart failure after an acute myocardial infarction." | 9.13 | Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. ( Beillat, M; de Pouvourville, G; Solesse, A, 2008) |
| "The EPHESUS study demonstrated that aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction (LVSD) and heart failure after acute myocardial infarction (AMI)." | 9.12 | Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. ( Burnier, M; Erne, P; Holm, MV; Schwenkglenks, M; Szucs, TD; Weintraub, WS; Zhang, Z, 2006) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction." | 9.11 | Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. ( Caro, J; Goldberg, R; Ishak, J; Kolm, P; Mahoney, EM; Pitt, B; Spertus, JA; Tooley, J; Weintraub, WS; Willke, R; Zhang, Z, 2005) |
| "To investigate the effect of spironolactone on left ventricular remodeling (LVRM) in patients with acute myocardial infarction." | 9.11 | [Effect of spironolactone on left ventricular remodeling in patients with acute myocardial infarction]. ( Dong, Q; Han, YP; Li, SR; Li, XC; Liu, G; Liu, HB; Liu, KS; Wang, XP; Wang, Y; Xu, LF; Zhang, LP, 2005) |
| "This study sought to assess the impact of the selective aldosterone blocker eplerenone on mortality 30 days after randomization in patients after acute myocardial infarction (AMI) with a left ventricular ejection fraction (LVEF) < or =40% and clinical signs of heart failure." | 9.11 | Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. ( Aschermann, M; Gheorghiade, M; Krum, H; Martinez, F; Mukherjee, R; Nicolau, J; Pitt, B; van Veldhuisen, DJ; Vincent, J; White, H; Zannad, F, 2005) |
| " We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure." | 9.10 | Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. ( Bittman, R; Gatlin, M; Hurley, S; Kleiman, J; Martinez, F; Neaton, J; Pitt, B; Remme, W; Roniker, B; Zannad, F, 2003) |
| " This manuscript provides an overview of the considerations made regarding quantification of a range of clinical and economic outcomes in the EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study) study, a 6200-patient, randomized, controlled trial of aldosterone blockade in patients with heart failure as a complication of acute myocardial infarction." | 9.10 | Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). ( Deedwania, P; Hurley, S; Jones, P; Mahoney, E; Pitt, B; Poston, C; Spertus, JA; Tooley, J; Weintraub, WS, 2002) |
| "Ramipril and spironolactone had similar effects on ventricular remodeling after acute myocardial infarction, suggesting that aldosterone contributes to this phenomenon and that inhibition of its receptor may be as effective as ACE inhibition in its prevention." | 9.08 | [Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study]. ( Castro, P; Chávez, A; Chávez, E; Corbalán, R; Godoy, I; Quintana, JC; Rodríguez, JA; Yovanovich, J, 1997) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 8.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| " The Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS) with eplerenone in patients who were post-myocardial infarction underscores the additive benefit of such a strategy in post-infarction patients that typify an at-risk population for recurrent cardiovascular events." | 8.82 | Eplerenone: will it have a role in the treatment of acute coronary syndromes? ( Meier, DJ; Pitt, B; Rajagopalan, S, 2004) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin II type 1 receptor antagonist on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 8.82 | Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. ( Omura, T; Yoshikawa, J; Yoshiyama, M, 2004) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 7.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "Spironolactone, the only aldosterone antagonist available in China, improves outcomes in acute myocardial infarction (AMI) among patients with systolic dysfunction and either diabetes or heart failure (HF)." | 7.81 | National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011. ( Desai, NR; Downing, N; Guan, W; Jiang, L; Krumholz, HM; Li, J; Li, X; Masoudi, FA; Murugiah, K; Ross, JS; Spertus, JA; Wang, Q, 2015) |
| "We sought to assess the effect of the aldosterone receptor blocker, spironolactone, on 1-year clinical outcomes in all-comers with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention." | 7.80 | Spironolactone lowers the rate of repeat revascularization in acute myocardial infarction patients treated with percutaneous coronary intervention. ( Ahn, Y; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jeong, MH; Kim, DI; Kim, DK; Kim, KH; Seo, GW; Seol, SH; Song, PS; Song, YB; Yang, JH, 2014) |
| "Our objective was to analyze the effect of spironolactone on cardiac remodeling after experimental myocardial infarction (MI), assessed by matricellular proteins levels, cardiac collagen amount and distribution, myocardial tissue metalloproteinase inhibitor-1 (TIMP-1) concentration, myocyte hypertrophy, left ventricular architecture, and in vitro and in vivo cardiac function." | 7.79 | Mechanisms involved in the beneficial effects of spironolactone after myocardial infarction. ( Azevedo, PS; Chiuso-Minicucci, F; dos Santos, PP; Gonçalves, AF; Minicucci, MF; Okoshi, K; Paiva, SA; Pereira, EJ; Polegato, BF; Rafacho, BP; Silva, RA; Zornoff, LA, 2013) |
| "We sought to assess possible interactions between eplerenone use and a plasma marker of collagen turnover on prognosis in patients after acute myocardial infarction (AMI) and preserved left ventricular (LV) ejection fraction (≥40%)." | 7.78 | Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone. ( Chalikias, G; Kampourides, N; Konstantinides, S; Maltezos, E; Papazoglou, D; Symeonides, D; Tziakas, D, 2012) |
| "The EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure and Survival Study) showed that the use of aldosterone blockade with eplerenone decreased mortality in patients with heart failure after acute myocardial infarction, and a subsequent analysis showed eplerenone to be highly cost effective in this population." | 7.76 | Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. ( Caro, J; Kolm, P; Mahoney, EM; Spertus, J; Weintraub, WS; Willke, R; Zhang, Z, 2010) |
| " Eplerenone is a new medicine that reduces the risk of death after myocardial infarction (MI) but produces additional cost to the health system." | 7.74 | Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone. ( de Bobadilla, JF; Farreras, V; Pinto-Prades, JL, 2008) |
| "The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs." | 7.74 | Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. ( Abuissa, H; O'Keefe, JH; Pitt, B, 2008) |
| "To examine the effects of eplerenone, a selective aldosterone blocker, on cardiac function after myocardial infarction (MI) and myocardial remodelling related transcriptional factors and mRNA expression in non-infarcted myocardium." | 7.73 | Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. ( Akioka, K; Enomoto, S; Iwao, H; Izumi, Y; Kim, S; Kusuyama, T; Matsumoto, R; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2005) |
| "Atrial fibrosis caused by chronic CHF is reduced by spironolactone." | 7.73 | Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 7.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| "In patients with severe left ventricular dysfunction (EF < 30%) after acute myocardial infarction long-term treatment with spironolactone at daily dose 25-50 mg does not reduce mortality rate in long-term follow-up." | 7.73 | [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "To investigate the effects of adding the selective aldosterone receptor antagonist eplerenone to ACE inhibition on endothelium-dependent vasodilation in rats with chronic heart failure (CHF)." | 7.72 | Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. ( Bauersachs, J; Ertl, G; Fraccarollo, D; Hildemann, SK; Schäfer, A; Tas, P, 2003) |
| " Because aldosterone production in the heart increases after myocardial infarction (MI), we investigated the effect of chronic administration of spironolactone, an aldosterone receptor antagonist, in rats after MI compared with the effects produced by losartan and hydralazine." | 7.72 | Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. ( de Resende, MM; Gomes, Mda G; Leite, CM; Milanez, Mda C; Mill, JG, 2003) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin-converting enzyme (ACE) inhibition on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 7.72 | Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Galuppo, P; Hildemann, S, 2003) |
| "Oral administration of spironolactone improves cardiac remodeling and its central infusion prevents the increase in sympathetic drive post-myocardial infarction (MI)." | 7.72 | Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. ( Lal, A; Leenen, FH; Veinot, JP, 2004) |
| "We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)." | 7.71 | Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001) |
| "Eplerenone was associated with a 1." | 6.74 | The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. ( Blair, JE; Gheorghiade, M; Harinstein, ME; Khan, S; Krum, H; Mukherjee, R; Pitt, B, 2009) |
| "Aldosterone blockade has been shown to be effective in reducing total mortality as well as hospitalization for heart failure in patients with systolic left ventricular dysfunction (SLVD) due to chronic heart failure and in patients with SLVD post acute myocardial infarction." | 6.42 | Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. ( Pitt, B, 2004) |
| "Eplerenone (Inspra) is a selective aldosterone blocker." | 6.42 | Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. ( Keating, GM; Plosker, GL, 2004) |
| "Increased fibrosis was accompanied by myofibroblast and macrophage infiltration in the heart and the kidney." | 5.62 | The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat. ( Leader, CJ; Walker, RJ; Wilkins, GT, 2021) |
| "The authors pooled data from 3 trials-CHARM Preserved (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity), I-Preserve (Irbesartan in Heart Failure With Preserved Systolic Function), and the Americas region of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) (N = 8,916)-and examined whether MI before or following enrollment independently predicted CV death and heart failure (HF) hospitalization." | 5.34 | Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. ( Anand, IS; Carson, P; Claggett, BL; Cunningham, JW; Desai, AS; Jhund, PS; John, JE; Kober, L; Lewis, EF; McMurray, JJV; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Swedberg, K; Vaduganathan, M; Yusuf, S; Zile, MR, 2020) |
| "Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI." | 5.33 | Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005) |
| "(8) Spironolactone remains the treatment of choice for patients with heart failure and incapacitating dyspnea despite ACE inhibitor and diuretic therapy." | 5.33 | Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. ( , 2006) |
| "In a sub-study of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS trial), BNP and BigET-1 were measured at baseline and at 1month in 476 patients." | 5.24 | Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac ( Bramlage, P; Fay, R; Girerd, N; Ketelslegers, JM; Michel, JB; Olivier, A; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2017) |
| " The investigation involved 6632 patients of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study." | 5.19 | Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s ( Challande, P; Fay, R; Lacolley, P; Lagrange, J; Pitt, B; Pizard, A; Regnault, V; Rossignol, P; Safar, ME; Zannad, F, 2014) |
| "EPHESUS was a multicentre, double-blind clinical trial in which 6632 patients with acute myocardial infarction (AMI) complicated by LV systolic dysfunction (LVSD) were randomized to receive eplerenone (n = 3319) or placebo (n = 3313)." | 5.19 | Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial. ( Adlam, D; Fay, R; Gunn, J; Iqbal, J; Parviz, Y; Pitt, B; Squire, I; Zannad, F, 2014) |
| "We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset." | 5.19 | Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. ( Flather, M; Hamm, CW; Lopez de Sa, E; Montalescot, G; Orri, M; Pitt, B; Shi, H; Turgonyi, E; Verheugt, F; Vincent, J; Zannad, F, 2014) |
| "The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI)." | 5.17 | Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction? ( Alihanoglu, Y; Bacaksiz, A; Demir, K; Gul, EE; Kayrak, M; Koc, F; Ozdemir, K; Sonmez, O; Tasal, A; Turfan, M; Vatankulu, MA; Yazici, M, 2013) |
| "We evaluated the effect of the selective mineralocorticoid receptor antagonist eplerenone on renal function and the interaction between changes in renal function and subsequent cardiovascular outcomes in patients with heart failure and left ventricular systolic dysfunction after an acute myocardial infarction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.16 | Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. ( Bhandari, S; Cleland, JG; Dobre, D; Fay, R; Gustafsson, F; Lamiral, Z; Pitt, B; Rossignol, P; Tala, S; Zannad, F, 2012) |
| "A total of 6,496 patients from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) were categorized into 4 groups by plasma glucose concentration: ≤4." | 5.16 | Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS. ( Böhm, M; Dobre, D; Kindermann, I; Lamiral, Z; Mahfoud, F; Pitt, B; Rossignol, P; Tala, S; Turgonyi, E; Ukena, C; Zannad, F, 2012) |
| "To evaluate the effects of spironolactone on cardiac sympathetic nerve activity (CSNA) and left ventricular (LV) remodelling in patients with ST-segment elevation myocardial infarction (STEMI)." | 5.15 | Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Minami, K; Sato, Y; Sumino, H; Takayama, Y; Toyama, T, 2011) |
| "We evaluated 12-month cost utilization data from 1516 heart failure outpatients enrolled in the Quality-of-Life Substudy of the Eplerenone Post-Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.14 | Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). ( Chan, PS; Jones, PG; Nallamothu, BK; Soto, G; Spertus, JA; Weintraub, WS; Zhang, Z, 2009) |
| "In a substudy of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), which evaluated the effects of the selective aldosterone receptor antagonist eplerenone versus placebo, serum levels of collagen biomarkers were measured in 476 patients with congestive heart failure after acute myocardial infarction complicated with left ventricular systolic dysfunction." | 5.14 | Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP ( Angioi, M; Fay, R; Iraqi, W; Ketelslegers, JM; Nuée, J; Pitt, B; Rossignol, P; Vincent, J; Zannad, F, 2009) |
| " Of the 6,632 patients with acute myocardial infarctions and left ventricular systolic dysfunction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), 4,407 had histories of hypertension." | 5.14 | A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction. ( Ahmed, A; Pitt, B, 2009) |
| " HRT from 24-hour Holter monitoring in 481 hospitalized patients after AMI with heart failure and/or diabetes with left ventricular dysfunction before randomization in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.14 | Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). ( Deedwania, P; Stein, PK, 2009) |
| "To test the hypothesis that an earlier post-acute myocardial infarction (AMI) eplerenone initiation in patients with left ventricular systolic dysfunction (LVSD) and heart failure (HF) is associated with better long-term outcomes." | 5.14 | Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. ( Adamopoulos, C; Ahmed, A; Angioi, M; Fay, R; Filippatos, G; Pitt, B; Vincent, J; Zannad, F, 2009) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN)." | 5.13 | History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. ( Ahmed, A; Aschermann, M; Cardoso, JS; Corbalán, R; Krum, H; Love, TE; Nicolau, J; Parkhomenko, A; Pitt, B; Shi, H; Solomon, H; Zannad, F, 2008) |
| "Hospitalized patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction (left ventricular ejection fraction < or =40%) treated with standard therapy were randomized 3 to 14 days after the acute myocardial infarction to additional treatment with eplerenone (25 to 50 mg/d; n=3319) or placebo (n=3313)." | 5.13 | Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). ( Bakris, G; DiCarlo, L; Mukherjee, R; Pitt, B; Ruilope, LM, 2008) |
| "The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) randomized clinical trial demonstrated the efficacy of eplerenone, a new aldosterone antagonist diuretic, with standard treatment versus standard treatment alone in the reduction of cardiovascular mortality and cardiovascular-related hospital readmissions for patients with heart failure after an acute myocardial infarction." | 5.13 | Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. ( Beillat, M; de Pouvourville, G; Solesse, A, 2008) |
"In EPHESUS, 6,632 patients with LVEF | 5.12 | Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction | |
| "The EPHESUS study demonstrated that aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction (LVSD) and heart failure after acute myocardial infarction (AMI)." | 5.12 | Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. ( Burnier, M; Erne, P; Holm, MV; Schwenkglenks, M; Szucs, TD; Weintraub, WS; Zhang, Z, 2006) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction." | 5.11 | Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. ( Caro, J; Goldberg, R; Ishak, J; Kolm, P; Mahoney, EM; Pitt, B; Spertus, JA; Tooley, J; Weintraub, WS; Willke, R; Zhang, Z, 2005) |
| "In RALES, low doses of the mineralocorticoid receptor (MR) antagonist spironolactone, added to standard of care for severe heart failure, improved survival by 30% and lowered hospitalization by 35%." | 5.11 | RALES, EPHESUS and redox. ( Funder, JW, 2005) |
| "To investigate the effect of spironolactone on left ventricular remodeling (LVRM) in patients with acute myocardial infarction." | 5.11 | [Effect of spironolactone on left ventricular remodeling in patients with acute myocardial infarction]. ( Dong, Q; Han, YP; Li, SR; Li, XC; Liu, G; Liu, HB; Liu, KS; Wang, XP; Wang, Y; Xu, LF; Zhang, LP, 2005) |
| "This study sought to assess the impact of the selective aldosterone blocker eplerenone on mortality 30 days after randomization in patients after acute myocardial infarction (AMI) with a left ventricular ejection fraction (LVEF) < or =40% and clinical signs of heart failure." | 5.11 | Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. ( Aschermann, M; Gheorghiade, M; Krum, H; Martinez, F; Mukherjee, R; Nicolau, J; Pitt, B; van Veldhuisen, DJ; Vincent, J; White, H; Zannad, F, 2005) |
| " We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure." | 5.10 | Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. ( Bittman, R; Gatlin, M; Hurley, S; Kleiman, J; Martinez, F; Neaton, J; Pitt, B; Remme, W; Roniker, B; Zannad, F, 2003) |
| "To evaluate the effect of mineralocorticoid receptor antagonist (MRA) spironolactone on post-infarct LV remodeling, 134 patients with first anterior acute myocardial infarction were randomly divided into the MRA (n=65) or non-MRA (n=69) groups after revascularization." | 5.10 | Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial in ( Fujii, M; Hamatani, T; Hayashi, M; Horie, M; Ishii, C; Kataoka, K; Kinoshita, M; Morigami, N; Nozato, Y; Ohnishi, M; Ohno, K; Taniguchi, A; Tsutamoto, T; Tsutsui, T; Wada, A, 2003) |
| " This manuscript provides an overview of the considerations made regarding quantification of a range of clinical and economic outcomes in the EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study) study, a 6200-patient, randomized, controlled trial of aldosterone blockade in patients with heart failure as a complication of acute myocardial infarction." | 5.10 | Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). ( Deedwania, P; Hurley, S; Jones, P; Mahoney, E; Pitt, B; Poston, C; Spertus, JA; Tooley, J; Weintraub, WS, 2002) |
| "Ramipril and spironolactone had similar effects on ventricular remodeling after acute myocardial infarction, suggesting that aldosterone contributes to this phenomenon and that inhibition of its receptor may be as effective as ACE inhibition in its prevention." | 5.08 | [Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study]. ( Castro, P; Chávez, A; Chávez, E; Corbalán, R; Godoy, I; Quintana, JC; Rodríguez, JA; Yovanovich, J, 1997) |
| "Two aldosterone inhibitors are currently licensed for heart failure (HF) in the UK: spironolactone and eplerenone." | 4.86 | A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. ( Bakhai, A; Burch, J; Fenwick, L; Harden, M; Lorgelly, P; McKenna, C; Palmer, S; Suekarran, S; Walker, S; Witte, K; Woolacott, N; Wright, K, 2010) |
| "Patients should be placed on the following medications: antiplatelet agents, (meta-analysis for aspirin, multiple randomized controlled trials [RCTs] for aspirin plus clopidogrel); a statin; atorvastatin has the best evidence (a single RCT); a beta-blocker (meta-analysis); renin-angiotensin-aldosterone system blockers, whether or not the ejection fraction is diminished after myocardial infarction (MI) (SOR: A, meta-analysis for angiotensin-converting enzyme [ACE] inhibitor; B, single RCT for ACE inhibitor plus aldosterone blocker)." | 4.86 | Clinical Inquiries: Which drugs should post-MI patients routinely receive? ( Holman, JR; Jamieson, B; Lin, V, 2010) |
| "Based on the RALES study, in patients with moderate to severe chronic heart failure and reduced left ventricular function, the nonselective aldosterone antagonist spironolactone has a well-established role in combination with ACE inhibition, beta-blockade and diuretics." | 4.83 | [Aldosterone receptor blockade after acute myocardial infarction with heart failure]. ( Bauersachs, J; Ertl, G, 2006) |
| " The selective aldosterone blocker, eplerenone (Inspra), is under development for human therapeutic use for treatment of hypertension and heart failure post-myocardial infarction (MI)." | 4.82 | Aldosterone target organ protection by eplerenone. ( McMahon, EG; Rocha, R; Rudolph, AE, 2004) |
| " Recently published data with a new aldosterone blocker, eplerenone, have confirmed the benefits of aldosterone blockade in patients post-myocardial infarction, as well as in the regression of left ventricular hypertrophy in hypertensive patients and of microalbuminuria in Type 2 diabetic patients." | 4.82 | Role of the selective aldosterone receptor blockers in arterial hypertension. ( Ruilope, LM; Sierra, C, 2004) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 4.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| " The Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS) with eplerenone in patients who were post-myocardial infarction underscores the additive benefit of such a strategy in post-infarction patients that typify an at-risk population for recurrent cardiovascular events." | 4.82 | Eplerenone: will it have a role in the treatment of acute coronary syndromes? ( Meier, DJ; Pitt, B; Rajagopalan, S, 2004) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin II type 1 receptor antagonist on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 4.82 | Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. ( Omura, T; Yoshikawa, J; Yoshiyama, M, 2004) |
| " Further proof of this hypothesis should be forthcoming from the results of the Eplerenone Heart Failure Efficacy and Survival Study (EPHESUS) early in 2003 in which the aldosterone receptor antagonist eplerenone is being evaluated in patients with systolic left ventricular dysfunction post myocardial infarction." | 4.81 | Do diuretics and aldosterone receptor antagonists improve ventricular remodeling? ( Pitt, B, 2002) |
| " Spironolactone may work through osteoblast MR/OCN axis to exert its therapeutic effects on pathological ventricular remodeling and heart failure in mice and human patients." | 4.12 | Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction. ( Bai, L; Chen, BY; Du, LJ; Duan, SZ; Guo, XG; Li, RG; Li, YL; Lin, WZ; Liu, T; Liu, Y; Ma, XX; Meng, XQ; Shao, S; Shi, XR; Sun, JY; Wang, YL; Zhou, LJ; Zhu, H, 2022) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 3.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "Acute myocardial infarction was induced in 60 rats via left coronary artery ligation: 50 animals were randomized to be euthanized after 1, 2, 4, 12, or 24 weeks; 10 animals were treated with eplerenone (100 mg/kg/days) 7 days before the AMI until their euthanasia (4 weeks later); 8 additional animals underwent surgery without ligation (control)." | 3.83 | The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction. ( Asensio-López, MC; Caballero, L; Fernández-Del Palacio, MJ; Gimeno-Blanes, JR; Lax, A; Navarro-Peñalver, M; Pascual-Figal, DA; Pérez-Martínez, MT; Sánchez-Más, J, 2016) |
| "Spironolactone, the only aldosterone antagonist available in China, improves outcomes in acute myocardial infarction (AMI) among patients with systolic dysfunction and either diabetes or heart failure (HF)." | 3.81 | National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011. ( Desai, NR; Downing, N; Guan, W; Jiang, L; Krumholz, HM; Li, J; Li, X; Masoudi, FA; Murugiah, K; Ross, JS; Spertus, JA; Wang, Q, 2015) |
| "We sought to assess the effect of the aldosterone receptor blocker, spironolactone, on 1-year clinical outcomes in all-comers with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention." | 3.80 | Spironolactone lowers the rate of repeat revascularization in acute myocardial infarction patients treated with percutaneous coronary intervention. ( Ahn, Y; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jeong, MH; Kim, DI; Kim, DK; Kim, KH; Seo, GW; Seol, SH; Song, PS; Song, YB; Yang, JH, 2014) |
| "Our objective was to analyze the effect of spironolactone on cardiac remodeling after experimental myocardial infarction (MI), assessed by matricellular proteins levels, cardiac collagen amount and distribution, myocardial tissue metalloproteinase inhibitor-1 (TIMP-1) concentration, myocyte hypertrophy, left ventricular architecture, and in vitro and in vivo cardiac function." | 3.79 | Mechanisms involved in the beneficial effects of spironolactone after myocardial infarction. ( Azevedo, PS; Chiuso-Minicucci, F; dos Santos, PP; Gonçalves, AF; Minicucci, MF; Okoshi, K; Paiva, SA; Pereira, EJ; Polegato, BF; Rafacho, BP; Silva, RA; Zornoff, LA, 2013) |
| "We sought to assess possible interactions between eplerenone use and a plasma marker of collagen turnover on prognosis in patients after acute myocardial infarction (AMI) and preserved left ventricular (LV) ejection fraction (≥40%)." | 3.78 | Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone. ( Chalikias, G; Kampourides, N; Konstantinides, S; Maltezos, E; Papazoglou, D; Symeonides, D; Tziakas, D, 2012) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial, hospitalized AMI patients complicated by left ventricular ejection fraction ≤40% and symptoms of HF receiving standard therapy were randomized 3-14 days post-AMI to receive eplerenone 25-50 mg/day (n = 3319) or placebo (n = 3313)." | 3.77 | Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. ( Aban, IB; Ahmed, A; Ahmed, MI; Deedwania, PC; Feller, MA; Love, TE; Pitt, B, 2011) |
| "The EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure and Survival Study) showed that the use of aldosterone blockade with eplerenone decreased mortality in patients with heart failure after acute myocardial infarction, and a subsequent analysis showed eplerenone to be highly cost effective in this population." | 3.76 | Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. ( Caro, J; Kolm, P; Mahoney, EM; Spertus, J; Weintraub, WS; Willke, R; Zhang, Z, 2010) |
| " Subsequently, gynecomastia developed as a side effect of spironolactone and digoxin treatment." | 3.75 | [A mourning case that referred with sexual identity disorder secondary to a general medical condition]. ( Ceri, O; Koçak, OM; Soykan, A; Tatlidil, E; Yilmaz, A, 2009) |
| " Eplerenone is a new medicine that reduces the risk of death after myocardial infarction (MI) but produces additional cost to the health system." | 3.74 | Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone. ( de Bobadilla, JF; Farreras, V; Pinto-Prades, JL, 2008) |
| "The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs." | 3.74 | Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. ( Abuissa, H; O'Keefe, JH; Pitt, B, 2008) |
| "To examine the effects of eplerenone, a selective aldosterone blocker, on cardiac function after myocardial infarction (MI) and myocardial remodelling related transcriptional factors and mRNA expression in non-infarcted myocardium." | 3.73 | Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. ( Akioka, K; Enomoto, S; Iwao, H; Izumi, Y; Kim, S; Kusuyama, T; Matsumoto, R; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2005) |
| "Atrial fibrosis caused by chronic CHF is reduced by spironolactone." | 3.73 | Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 3.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| "In patients with severe left ventricular dysfunction (EF < 30%) after acute myocardial infarction long-term treatment with spironolactone at daily dose 25-50 mg does not reduce mortality rate in long-term follow-up." | 3.73 | [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "To investigate the effects of adding the selective aldosterone receptor antagonist eplerenone to ACE inhibition on endothelium-dependent vasodilation in rats with chronic heart failure (CHF)." | 3.72 | Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. ( Bauersachs, J; Ertl, G; Fraccarollo, D; Hildemann, SK; Schäfer, A; Tas, P, 2003) |
| " Because aldosterone production in the heart increases after myocardial infarction (MI), we investigated the effect of chronic administration of spironolactone, an aldosterone receptor antagonist, in rats after MI compared with the effects produced by losartan and hydralazine." | 3.72 | Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. ( de Resende, MM; Gomes, Mda G; Leite, CM; Milanez, Mda C; Mill, JG, 2003) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin-converting enzyme (ACE) inhibition on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 3.72 | Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. ( Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Galuppo, P; Hildemann, S, 2003) |
| "In mice with MI, eplerenone attenuates progression of heart failure comparably to ACEi, and its effect is independent of BP lowering." | 3.72 | Role of a selective aldosterone blocker in mice with chronic heart failure. ( Carretero, OA; Liu, YH; Peterson, E; Rhaleb, NE; Rudolph, AE; Wang, D; Xu, J; Yang, XP, 2004) |
| "Because the effects of an aldosterone receptor antagonist on transcriptional factors and mRNA expression have not been fully examined in myocardial infarction (MI), the present study examined the effects of spironolactone (SPIRO) and candesartan cilexitil (CAN) on activation of activator protein-1 (AP-1), nuclear factor-kappaB (NF-kappaB) and mRNA expression in the non-ischemic myocardium after MI." | 3.72 | Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction. ( Akioka, K; Iwao, H; Izumi, Y; Kim, S; Matsumoto, R; Nakamura, Y; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2004) |
| "Oral administration of spironolactone improves cardiac remodeling and its central infusion prevents the increase in sympathetic drive post-myocardial infarction (MI)." | 3.72 | Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. ( Lal, A; Leenen, FH; Veinot, JP, 2004) |
| "The mineralocorticoid (MC) receptor antagonist spironolactone (SL) improves morbidity and mortality in patients with congestive heart failure (CHF)." | 3.71 | Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. ( Beltz, TG; Felder, RB; Francis, J; Johnson, AK; Wei, SG; Weiss, RM; Zimmerman, K, 2001) |
| "We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)." | 3.71 | Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001) |
| " Plasma samples from non-digitalized patients of the following categories were assayed: uncomplicated essential hypertension treated with spironolactone, uremia, and acute myocardial infarction (AMI)." | 3.66 | Precision of digoxin radioimmunoassays and matrix effects: four kits compared. ( Bergdähl, B; Molin, L, 1981) |
| "Following a description of hemodynamic and metabolic effects of an acute myocardial infarction, indications for a therapy with furosemide, isosorbiddinitrate, digitalis, canrenoate-potassium, and dopamine and the results thereof are discussed." | 3.65 | [New aspects of treatment of hemodynamic complications in acute myocardial infarction (author's transl)]. ( Schröder, R, 1977) |
| "Additionally, ischemic heart disease adversely impacts the clinical course of HFrEF patients; however, its role in HFpEF is not fully understood." | 3.01 | Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). ( Elsaid, O; McCullough, PA; Rahimi, G; Tecson, KM, 2021) |
| "Eplerenone was associated with a 1." | 2.74 | The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. ( Blair, JE; Gheorghiade, M; Harinstein, ME; Khan, S; Krum, H; Mukherjee, R; Pitt, B, 2009) |
| "Hyperaldosteronism was confirmed in 74% of 72 consecutive patients admitted for acute myocardial infarction, in 85% if patients previously treated by an antialdosterone drug or admitted after the acute phase are excluded, and in 96% if patients with cardiac failure are included." | 2.65 | [Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation]. ( Denis, B; Dimitriou, R; Machecourt, J; Page, E; Reboud, JP; Wolf, JE, 1984) |
| "Hyperkalemia is the main potential side effect of eplerenone, especially when used in combination with other medications that can cause hyperkalemia." | 2.46 | Review article: eplerenone: an underused medication? ( Abuannadi, M; O'Keefe, JH, 2010) |
| "Aldosterone blockade has been shown to be effective in reducing total mortality as well as hospitalization for heart failure in patients with systolic left ventricular dysfunction (SLVD) due to chronic heart failure and in patients with SLVD post acute myocardial infarction." | 2.42 | Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. ( Pitt, B, 2004) |
| "Eplerenone (Inspra) is a selective aldosterone blocker." | 2.42 | Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. ( Keating, GM; Plosker, GL, 2004) |
| "Increased fibrosis was accompanied by myofibroblast and macrophage infiltration in the heart and the kidney." | 1.62 | The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat. ( Leader, CJ; Walker, RJ; Wilkins, GT, 2021) |
| "Spironolactone was the predominantly prescribed aldosterone antagonist." | 1.43 | Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. ( Das, S; de Lemos, JA; Fonarow, GC; Peng, SA; Peterson, ED; Vora, AN; Wang, TY, 2016) |
| "Spironolactone is a promising therapeutic option for alleviating remodeling after left ventricular restoration." | 1.35 | Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery. ( Ikeda, T; Kanemitsu, H; Komeda, M; Marui, A; Nishina, T; Tsukashita, M; Wang, J; Yoshikawa, E, 2008) |
| "Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI." | 1.33 | Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005) |
| "(8) Spironolactone remains the treatment of choice for patients with heart failure and incapacitating dyspnea despite ACE inhibitor and diuretic therapy." | 1.33 | Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. ( , 2006) |
| "Infarct healing and left ventricular remodeling were evaluated at 3, 7, and 28 days after MI by determination of the diastolic pressure-volume relationship of the left ventricle, the infarct-thinning ratio, and the collagen-volume fraction." | 1.31 | Effect of a selective aldosterone receptor antagonist in myocardial infarction. ( Delyani, JA; Robinson, EL; Rudolph, AE, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (10.70) | 18.7374 |
| 1990's | 1 (0.47) | 18.2507 |
| 2000's | 116 (53.95) | 29.6817 |
| 2010's | 64 (29.77) | 24.3611 |
| 2020's | 11 (5.12) | 2.80 |
| Authors | Studies |
|---|---|
| Vakaliuk, IP | 1 |
| Savchuk, NV | 1 |
| Nesterak, RV | 1 |
| Kulynych, HB | 1 |
| Hryhoryshyn, RS | 1 |
| Pitt, B | 37 |
| Ferreira, JP | 5 |
| Zannad, F | 22 |
| Leader, CJ | 1 |
| Wilkins, GT | 1 |
| Walker, RJ | 1 |
| Weir, RAP | 1 |
| Clements, S | 8 |
| Steedman, T | 11 |
| Dargie, HJ | 11 |
| McMurray, JJV | 3 |
| Martens, P | 1 |
| Vincent, J | 8 |
| Abreu, P | 1 |
| Busselen, M | 1 |
| Mullens, W | 1 |
| Tang, WHW | 1 |
| Böhm, M | 2 |
| Rossignol, P | 10 |
| Wang, YL | 1 |
| Bai, L | 1 |
| Shi, XR | 1 |
| Zhu, H | 1 |
| Du, LJ | 1 |
| Liu, Y | 2 |
| Ma, XX | 1 |
| Lin, WZ | 1 |
| Liu, T | 1 |
| Sun, JY | 1 |
| Guo, XG | 1 |
| Zhou, LJ | 1 |
| Chen, BY | 1 |
| Shao, S | 1 |
| Meng, XQ | 1 |
| Li, YL | 1 |
| Li, RG | 1 |
| Duan, SZ | 1 |
| Bedrouni, W | 1 |
| Sharma, A | 1 |
| Lam, CSP | 1 |
| Ni, J | 1 |
| McMurray, J | 2 |
| Giannetti, N | 1 |
| Girerd, N | 3 |
| Solomon, SD | 3 |
| Claggett, B | 1 |
| Pocock, S | 1 |
| Huynh, T | 1 |
| Stienen, S | 1 |
| Cleland, JG | 2 |
| Pellicori, P | 1 |
| Krasnova, M | 1 |
| Kulikov, A | 1 |
| Okovityi, S | 1 |
| Ivkin, D | 1 |
| Karpov, A | 1 |
| Kaschina, E | 1 |
| Smirnov, A | 1 |
| Cunningham, JW | 1 |
| Vaduganathan, M | 1 |
| Claggett, BL | 1 |
| John, JE | 1 |
| Desai, AS | 1 |
| Lewis, EF | 1 |
| Zile, MR | 1 |
| Carson, P | 1 |
| Jhund, PS | 1 |
| Kober, L | 1 |
| Shah, SJ | 1 |
| Swedberg, K | 2 |
| Anand, IS | 1 |
| Yusuf, S | 1 |
| Pfeffer, MA | 2 |
| Rahimi, G | 1 |
| Tecson, KM | 1 |
| Elsaid, O | 1 |
| McCullough, PA | 1 |
| Sandesara, PB | 1 |
| Hammadah, M | 1 |
| Samman-Tahhan, A | 1 |
| Kelli, HM | 1 |
| O'Neal, WT | 1 |
| Franken, PR | 1 |
| Woltersdorf, R | 1 |
| Löfman, I | 1 |
| Szummer, K | 1 |
| Olsson, H | 1 |
| Carrero, JJ | 1 |
| Lund, LH | 1 |
| Jernberg, T | 1 |
| Duarte, K | 1 |
| van Veldhuisen, DJ | 6 |
| Ahmad, T | 2 |
| Tromp, J | 1 |
| Tsujimoto, T | 1 |
| Kajio, H | 1 |
| Gastelurrutia, P | 1 |
| Lupón, J | 1 |
| Bayes-Genis, A | 1 |
| Weir, RA | 11 |
| Petrie, CJ | 8 |
| Murphy, CA | 5 |
| Miller, AM | 4 |
| McInnes, IB | 4 |
| Squire, IB | 5 |
| Ng, LL | 5 |
| McMurray, JJ | 10 |
| Squara, P | 1 |
| Januzzi, JL | 1 |
| Minicucci, MF | 1 |
| dos Santos, PP | 1 |
| Rafacho, BP | 1 |
| Gonçalves, AF | 1 |
| Silva, RA | 1 |
| Chiuso-Minicucci, F | 1 |
| Azevedo, PS | 1 |
| Polegato, BF | 1 |
| Okoshi, K | 1 |
| Pereira, EJ | 1 |
| Paiva, SA | 1 |
| Zornoff, LA | 1 |
| Regnault, V | 1 |
| Lagrange, J | 1 |
| Pizard, A | 1 |
| Safar, ME | 1 |
| Fay, R | 7 |
| Challande, P | 1 |
| Lacolley, P | 1 |
| Overbeck, P | 1 |
| Carillo, S | 1 |
| Zhang, Y | 1 |
| Angioi, M | 3 |
| Sutradhor, SC | 1 |
| Ahmed, A | 5 |
| Iqbal, J | 1 |
| Adlam, D | 1 |
| Squire, I | 1 |
| Parviz, Y | 1 |
| Gunn, J | 1 |
| Scirica, BM | 1 |
| Montalescot, G | 3 |
| Lopez de Sa, E | 1 |
| Hamm, CW | 1 |
| Flather, M | 1 |
| Verheugt, F | 1 |
| Shi, H | 2 |
| Turgonyi, E | 2 |
| Orri, M | 1 |
| Roe, MT | 1 |
| Rafatian, N | 1 |
| Westcott, KV | 1 |
| White, RA | 1 |
| Leenen, FH | 5 |
| Song, PS | 1 |
| Kim, DK | 1 |
| Seo, GW | 1 |
| Kim, KH | 1 |
| Seol, SH | 1 |
| Yang, JH | 1 |
| Hahn, JY | 1 |
| Choi, SH | 1 |
| Choi, JH | 1 |
| Gwon, HC | 1 |
| Ahn, Y | 1 |
| Jeong, MH | 1 |
| Song, YB | 1 |
| Kim, DI | 1 |
| Fiuzat, M | 1 |
| Burnett, JC | 1 |
| Bulluck, H | 1 |
| Fröhlich, GM | 1 |
| Mohdnazri, S | 1 |
| Gamma, RA | 1 |
| Davies, JR | 1 |
| Clesham, GJ | 1 |
| Sayer, JW | 1 |
| Aggarwal, RK | 1 |
| Tang, KH | 1 |
| Kelly, PA | 1 |
| Jagathesan, R | 1 |
| Kabir, A | 1 |
| Robinson, NM | 1 |
| Sirker, A | 1 |
| Mathur, A | 1 |
| Blackman, DJ | 1 |
| Ariti, C | 1 |
| Krishnamurthy, A | 1 |
| White, SK | 1 |
| Meier, P | 1 |
| Moon, JC | 1 |
| Greenwood, JP | 1 |
| Hausenloy, DJ | 1 |
| Yu, HD | 1 |
| Xia, S | 1 |
| Zha, CQ | 1 |
| Deng, SB | 1 |
| Du, JL | 1 |
| She, Q | 1 |
| Guan, W | 1 |
| Murugiah, K | 1 |
| Downing, N | 1 |
| Li, J | 1 |
| Wang, Q | 1 |
| Ross, JS | 1 |
| Desai, NR | 1 |
| Masoudi, FA | 1 |
| Spertus, JA | 6 |
| Li, X | 1 |
| Krumholz, HM | 2 |
| Jiang, L | 1 |
| Wang, TY | 1 |
| Vora, AN | 1 |
| Peng, SA | 1 |
| Fonarow, GC | 1 |
| Das, S | 1 |
| de Lemos, JA | 1 |
| Peterson, ED | 1 |
| Beygui, F | 2 |
| Cayla, G | 1 |
| Roule, V | 1 |
| Roubille, F | 1 |
| Delarche, N | 1 |
| Silvain, J | 1 |
| Van Belle, E | 1 |
| Belle, L | 1 |
| Galinier, M | 1 |
| Motreff, P | 1 |
| Cornillet, L | 1 |
| Collet, JP | 1 |
| Furber, A | 2 |
| Goldstein, P | 1 |
| Ecollan, P | 1 |
| Legallois, D | 1 |
| Lebon, A | 1 |
| Rousseau, H | 1 |
| Machecourt, J | 2 |
| Vicaut, E | 2 |
| Sánchez-Más, J | 1 |
| Lax, A | 1 |
| Asensio-López, MC | 1 |
| Fernández-Del Palacio, MJ | 1 |
| Caballero, L | 1 |
| Navarro-Peñalver, M | 1 |
| Pérez-Martínez, MT | 1 |
| Gimeno-Blanes, JR | 1 |
| Pascual-Figal, DA | 1 |
| Olivier, A | 1 |
| Michel, JB | 1 |
| Ketelslegers, JM | 2 |
| Bramlage, P | 1 |
| Love, TE | 2 |
| Krum, H | 6 |
| Nicolau, J | 2 |
| Cardoso, JS | 1 |
| Parkhomenko, A | 3 |
| Aschermann, M | 2 |
| Corbalán, R | 3 |
| Solomon, H | 2 |
| Tsukashita, M | 1 |
| Marui, A | 1 |
| Nishina, T | 1 |
| Yoshikawa, E | 1 |
| Kanemitsu, H | 1 |
| Wang, J | 2 |
| Ikeda, T | 1 |
| Komeda, M | 1 |
| Bakris, G | 1 |
| Ruilope, LM | 2 |
| DiCarlo, L | 1 |
| Mukherjee, R | 4 |
| Ramaraj, R | 1 |
| de Pouvourville, G | 1 |
| Solesse, A | 1 |
| Beillat, M | 1 |
| Chan, PS | 1 |
| Soto, G | 1 |
| Jones, PG | 1 |
| Nallamothu, BK | 1 |
| Zhang, Z | 4 |
| Weintraub, WS | 6 |
| Uzunhasan, I | 1 |
| Yildiz, A | 1 |
| Coskun, U | 1 |
| Kalyoncuoglu, M | 1 |
| Baskurt, M | 1 |
| Cakar, MA | 1 |
| Kaya, A | 1 |
| Pehlivanoglu, S | 1 |
| Enar, R | 1 |
| Okcun, B | 1 |
| Chong, KS | 1 |
| Dalzell, JR | 1 |
| Mark, PB | 2 |
| McDonagh, TA | 1 |
| van den Borne, SW | 1 |
| Isobe, S | 1 |
| Zandbergen, HR | 1 |
| Li, P | 1 |
| Petrov, A | 1 |
| Wong, ND | 1 |
| Fujimoto, S | 1 |
| Fujimoto, A | 1 |
| Lovhaug, D | 1 |
| Smits, JF | 1 |
| Daemen, MJ | 1 |
| Blankesteijn, WM | 1 |
| Reutelingsperger, C | 1 |
| Narula, N | 1 |
| Vannan, MA | 1 |
| Hofstra, L | 1 |
| Narula, J | 1 |
| Iraqi, W | 1 |
| Nuée, J | 1 |
| Stein, PK | 1 |
| Deedwania, P | 2 |
| Ford, I | 1 |
| Wagner, GS | 3 |
| Yilmaz, A | 1 |
| Ceri, O | 1 |
| Tatlidil, E | 1 |
| Koçak, OM | 1 |
| Soykan, A | 1 |
| Balmain, S | 2 |
| Rumley, A | 1 |
| Lowe, GD | 1 |
| Gheorghiade, M | 4 |
| Khan, S | 1 |
| Blair, JE | 1 |
| Harinstein, ME | 1 |
| Mihailidou, AS | 2 |
| Loan Le, TY | 2 |
| Mardini, M | 2 |
| Funder, JW | 3 |
| Adamopoulos, C | 1 |
| Filippatos, G | 1 |
| Schmidt, K | 1 |
| Tissier, R | 1 |
| Ghaleh, B | 1 |
| Drogies, T | 1 |
| Felix, SB | 1 |
| Krieg, T | 1 |
| Kanashiro-Takeuchi, RM | 1 |
| Heidecker, B | 1 |
| Lamirault, G | 1 |
| Dharamsi, JW | 1 |
| Hare, JM | 1 |
| Mahoney, EM | 2 |
| Kolm, P | 2 |
| Spertus, J | 1 |
| Caro, J | 2 |
| Willke, R | 2 |
| Murphy, GE | 1 |
| Connell, JM | 2 |
| Maron, BA | 1 |
| Leopold, JA | 1 |
| Martin, TN | 2 |
| McKenna, C | 1 |
| Burch, J | 1 |
| Suekarran, S | 1 |
| Walker, S | 1 |
| Bakhai, A | 1 |
| Witte, K | 1 |
| Harden, M | 1 |
| Wright, K | 1 |
| Woolacott, N | 1 |
| Lorgelly, P | 1 |
| Fenwick, L | 1 |
| Palmer, S | 1 |
| Lopukhova, VV | 1 |
| Sapel'nikov, OV | 1 |
| Grishin, IR | 1 |
| Erastova, NV | 1 |
| Latypov, RS | 1 |
| Mareev, IuV | 1 |
| Chernova, NA | 1 |
| Saidova, MA | 1 |
| Akchurin, RS | 1 |
| Karpov, IuA | 1 |
| Martinez, FA | 1 |
| Lin, V | 1 |
| Holman, JR | 1 |
| Jamieson, B | 1 |
| Abuannadi, M | 1 |
| O'Keefe, JH | 2 |
| Kayrak, M | 2 |
| Bacaksiz, A | 2 |
| Vatankulu, MA | 2 |
| Ayhan, SS | 1 |
| Ari, H | 1 |
| Kaya, Z | 1 |
| Ozdemir, K | 2 |
| Santini, M | 1 |
| Pignalberi, C | 1 |
| de Peuter, OR | 1 |
| Lip, GY | 1 |
| Souverein, PC | 1 |
| Klungel, OH | 1 |
| de Boer, A | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Kasama, S | 1 |
| Toyama, T | 1 |
| Sumino, H | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Minami, K | 1 |
| Ichikawa, S | 1 |
| Matsumoto, N | 1 |
| Sato, Y | 1 |
| Kurabayashi, M | 1 |
| Deedwania, PC | 1 |
| Ahmed, MI | 1 |
| Feller, MA | 1 |
| Aban, IB | 1 |
| Vergaro, G | 1 |
| Emdin, M | 1 |
| Iervasi, A | 1 |
| Zyw, L | 1 |
| Gabutti, A | 1 |
| Poletti, R | 1 |
| Mammini, C | 1 |
| Giannoni, A | 1 |
| Fontana, M | 1 |
| Passino, C | 1 |
| Boccanelli, A | 1 |
| Agostoni, P | 1 |
| Tsorlalis, IK | 1 |
| Fraser, R | 1 |
| Torigoe, K | 1 |
| Tamura, A | 1 |
| Kawano, Y | 1 |
| Shinozaki, K | 1 |
| Kotoku, M | 1 |
| Kadota, J | 1 |
| Bhandari, S | 1 |
| Tala, S | 2 |
| Gustafsson, F | 1 |
| Lamiral, Z | 3 |
| Dobre, D | 3 |
| Chabot, A | 1 |
| Jiang, BH | 1 |
| Shi, Y | 1 |
| Tardif, JC | 1 |
| Dupuis, J | 1 |
| Homma, T | 1 |
| Sonoda, H | 1 |
| Manabe, K | 1 |
| Arai, K | 1 |
| Mizuno, M | 1 |
| Sada, T | 1 |
| Ikeda, M | 1 |
| Butler, J | 1 |
| Ezekowitz, JA | 1 |
| Collins, SP | 1 |
| Givertz, MM | 1 |
| Teerlink, JR | 2 |
| Walsh, MN | 1 |
| Albert, NM | 1 |
| Westlake Canary, CA | 1 |
| Carson, PE | 1 |
| Colvin-Adams, M | 1 |
| Fang, JC | 1 |
| Hernandez, AF | 1 |
| Hershberger, RE | 1 |
| Katz, SD | 1 |
| Rogers, JG | 1 |
| Stevenson, WG | 1 |
| Sweitzer, NK | 1 |
| Tang, WH | 1 |
| Stough, WG | 1 |
| Starling, RC | 1 |
| Howell, VM | 1 |
| Ashton, AW | 1 |
| Noda, K | 1 |
| Kobara, M | 2 |
| Hamada, J | 1 |
| Yoshifuji, Y | 1 |
| Shiraishi, T | 1 |
| Tanaka, T | 1 |
| Toba, H | 1 |
| Nakata, T | 1 |
| Ukena, C | 1 |
| Mahfoud, F | 1 |
| Kindermann, I | 1 |
| Kampourides, N | 1 |
| Tziakas, D | 1 |
| Chalikias, G | 1 |
| Papazoglou, D | 1 |
| Maltezos, E | 1 |
| Symeonides, D | 1 |
| Konstantinides, S | 1 |
| Murin, J | 1 |
| Sonmez, O | 1 |
| Alihanoglu, Y | 1 |
| Koc, F | 1 |
| Demir, K | 1 |
| Gul, EE | 1 |
| Turfan, M | 1 |
| Tasal, A | 1 |
| Yazici, M | 1 |
| Sanderson, JE | 1 |
| Jessup, M | 1 |
| Remme, W | 2 |
| Neaton, J | 2 |
| Martinez, F | 3 |
| Roniker, B | 2 |
| Bittman, R | 2 |
| Hurley, S | 3 |
| Kleiman, J | 2 |
| Gatlin, M | 1 |
| Hayashi, M | 2 |
| Tsutamoto, T | 2 |
| Wada, A | 1 |
| Tsutsui, T | 1 |
| Ishii, C | 1 |
| Ohno, K | 1 |
| Fujii, M | 1 |
| Taniguchi, A | 1 |
| Hamatani, T | 1 |
| Nozato, Y | 1 |
| Kataoka, K | 1 |
| Morigami, N | 1 |
| Ohnishi, M | 1 |
| Kinoshita, M | 1 |
| Horie, M | 1 |
| Aaronson, K | 1 |
| Schäfer, A | 1 |
| Fraccarollo, D | 5 |
| Hildemann, SK | 1 |
| Tas, P | 1 |
| Ertl, G | 6 |
| Bauersachs, J | 6 |
| Massie, BM | 1 |
| Aggarwal, A | 1 |
| Coca, SG | 1 |
| Buller, GK | 1 |
| Blaustein, DA | 1 |
| Schwenk, MH | 1 |
| Biondi-Zoccai, GG | 1 |
| Abbate, A | 1 |
| Baldi, A | 1 |
| Doggrell, S | 1 |
| Hackam, DG | 1 |
| Trifonov, IR | 1 |
| BRILLANTE, C | 1 |
| CHIERICI, F | 1 |
| SURIANI, L | 1 |
| MANZINI, E | 1 |
| RAAB, W | 1 |
| Mill, JG | 1 |
| Milanez, Mda C | 1 |
| de Resende, MM | 1 |
| Gomes, Mda G | 1 |
| Leite, CM | 1 |
| SoRelle, R | 1 |
| Galuppo, P | 4 |
| Hildemann, S | 1 |
| Christ, M | 2 |
| Rochetaing, A | 1 |
| Chapon, C | 1 |
| Marescaux, L | 1 |
| Le Bouil, A | 1 |
| Kreher, P | 1 |
| Wang, D | 1 |
| Liu, YH | 1 |
| Yang, XP | 1 |
| Rhaleb, NE | 1 |
| Xu, J | 1 |
| Peterson, E | 1 |
| Rudolph, AE | 4 |
| Carretero, OA | 1 |
| von Haehling, S | 1 |
| Grimm, W | 1 |
| Maisch, B | 1 |
| Matsumoto, R | 2 |
| Yoshiyama, M | 3 |
| Omura, T | 3 |
| Kim, S | 2 |
| Nakamura, Y | 1 |
| Izumi, Y | 2 |
| Akioka, K | 2 |
| Iwao, H | 2 |
| Takeuchi, K | 2 |
| Yoshikawa, J | 3 |
| Rocha, R | 1 |
| McMahon, EG | 2 |
| Sierra, C | 1 |
| Liew, D | 1 |
| Adams, KF | 1 |
| Nolan, PE | 1 |
| Meier, DJ | 1 |
| Rajagopalan, S | 1 |
| Thohan, V | 1 |
| Torre-Amione, G | 1 |
| Koerner, MM | 1 |
| Soto, GE | 1 |
| Jones, P | 2 |
| Perrier, E | 1 |
| Kerfant, BG | 1 |
| Lalevee, N | 1 |
| Bideaux, P | 1 |
| Rossier, MF | 1 |
| Richard, S | 1 |
| Gómez, AM | 1 |
| Benitah, JP | 1 |
| Masson, S | 1 |
| Staszewsky, L | 1 |
| Annoni, G | 1 |
| Carlo, E | 1 |
| Arosio, B | 1 |
| Bai, A | 1 |
| Calabresi, C | 1 |
| Martinoli, E | 1 |
| Salio, M | 1 |
| Fiordaliso, F | 1 |
| Scanziani, E | 1 |
| Latini, R | 1 |
| Keating, GM | 1 |
| Plosker, GL | 1 |
| Lal, A | 2 |
| Veinot, JP | 2 |
| Dzau, VJ | 1 |
| Huang, BS | 1 |
| Ostrenga, A | 1 |
| Pitcock, J | 1 |
| Pitcock, M | 1 |
| Conti, CR | 2 |
| Ishak, J | 1 |
| Goldberg, R | 1 |
| Tooley, J | 2 |
| Micheletta, F | 1 |
| Natoli, S | 1 |
| Iuliano, L | 1 |
| Heinzl, S | 1 |
| Enomoto, S | 1 |
| Kusuyama, T | 1 |
| Katada, J | 1 |
| Meguro, T | 1 |
| Saito, H | 1 |
| Ohashi, A | 1 |
| Anzai, T | 1 |
| Ogawa, S | 1 |
| Yoshikawa, T | 1 |
| Dong, Q | 1 |
| Liu, KS | 1 |
| Liu, HB | 1 |
| Li, SR | 1 |
| Han, YP | 1 |
| Zhang, LP | 1 |
| Wang, Y | 1 |
| Liu, G | 1 |
| Wang, XP | 1 |
| Xu, LF | 1 |
| Li, XC | 1 |
| Schmidt, I | 1 |
| Ganten, D | 1 |
| White, H | 1 |
| Stecker, EC | 1 |
| McAnulty, JH | 1 |
| Milliez, P | 1 |
| Deangelis, N | 1 |
| Rucker-Martin, C | 1 |
| Leenhardt, A | 1 |
| Robidel, E | 1 |
| Beaufils, P | 1 |
| Delcayre, C | 1 |
| Hatem, SN | 1 |
| Kessler-Icekson, G | 1 |
| Schlesinger, H | 1 |
| Freimann, S | 1 |
| Kessler, E | 1 |
| Chai, W | 1 |
| Garrelds, IM | 1 |
| de Vries, R | 1 |
| Danser, AH | 1 |
| Anderson, JL | 1 |
| Klug, EQ | 1 |
| Szucs, TD | 1 |
| Holm, MV | 1 |
| Schwenkglenks, M | 1 |
| Burnier, M | 1 |
| Erne, P | 1 |
| Mundhenke, M | 1 |
| Ferrari, R | 1 |
| Lopez-Sendon, J | 2 |
| Urabe, A | 1 |
| Izumi, T | 1 |
| Abe, Y | 1 |
| Taniguchi, I | 1 |
| Mochizuki, S | 1 |
| van der Horst, IC | 1 |
| Voors, AA | 1 |
| Szabo, S | 1 |
| Oikonomopoulos, T | 1 |
| Hoffmeister, HM | 1 |
| Pinto-Prades, JL | 1 |
| Farreras, V | 1 |
| de Bobadilla, JF | 1 |
| Abuissa, H | 1 |
| Watanabe, J | 1 |
| Takeda, M | 1 |
| Tatsumi, T | 1 |
| Matsunaga, S | 1 |
| Hayashi, H | 1 |
| Kimata, M | 1 |
| Honsho, S | 1 |
| Nishikawa, S | 1 |
| Mano, A | 1 |
| Shiraishi, J | 1 |
| Yamada, H | 1 |
| Takahashi, T | 1 |
| Matoba, S | 1 |
| Matsubara, H | 1 |
| Ruta, J | 1 |
| Ptaszyński, P | 1 |
| Maciejewski, M | 1 |
| Chizyński, K | 1 |
| Goch, JH | 1 |
| Sartório, CL | 1 |
| Leutke, M | 1 |
| Stefanon, I | 1 |
| Brandes, RP | 1 |
| Verma, A | 1 |
| Schraut, S | 1 |
| Kneitz, S | 1 |
| van Rooijen, N | 1 |
| Denis, B | 1 |
| Dimitriou, R | 1 |
| Wolf, JE | 1 |
| Page, E | 1 |
| Reboud, JP | 1 |
| Kun, IS | 1 |
| Ostrovskaia, VI | 1 |
| Abinder, AA | 1 |
| Bergdähl, B | 1 |
| Molin, L | 1 |
| Rodríguez, JA | 1 |
| Godoy, I | 1 |
| Castro, P | 1 |
| Quintana, JC | 1 |
| Chávez, E | 1 |
| Yovanovich, J | 1 |
| Chávez, A | 1 |
| Armstrong, PW | 1 |
| Delyani, JA | 1 |
| Robinson, EL | 1 |
| Williams, G | 1 |
| Burns, D | 1 |
| Francis, J | 1 |
| Weiss, RM | 1 |
| Wei, SG | 1 |
| Johnson, AK | 1 |
| Beltz, TG | 1 |
| Zimmerman, K | 1 |
| Felder, RB | 1 |
| Beck, L | 1 |
| Blanc-Guillemaud, V | 1 |
| Cherif, OK | 1 |
| Jover, B | 1 |
| Davy, JM | 1 |
| Gronda, E | 1 |
| Mangiavacchi, M | 1 |
| Andreuzzi, B | 1 |
| Municinò, A | 1 |
| Poston, C | 1 |
| Mahoney, E | 1 |
| Wilhelmsen, L | 1 |
| Berglund, G | 1 |
| Sannerstedt, R | 1 |
| Hansson, L | 1 |
| Andersson, O | 1 |
| Sievertsson, R | 1 |
| Wikstrand, J | 1 |
| Ames, RP | 1 |
| Hill, P | 1 |
| Schröder, R | 3 |
| Drozdova, ES | 1 |
| Wexler, BC | 1 |
| Osswald, H | 1 |
| Selye, H | 2 |
| Lvoff, R | 1 |
| Wilcken, DE | 1 |
| Kötter, V | 1 |
| von Leitner, E | 2 |
| Arbeiter, G | 1 |
| Cordes, R | 1 |
| Kuhlmann, J | 1 |
| Fleming, JS | 1 |
| Ramdohr, B | 1 |
| Sadée, W | 1 |
| Dagcioglu, M | 1 |
| Arora, RB | 1 |
| Savoie, L | 1 |
| Krajny, M | 1 |
| Kleiman, B | 1 |
| Kühn, P | 1 |
| Probst, P | 1 |
| Alekseeva, LA | 1 |
| Kjeldsen, K | 1 |
| Sand, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure[NCT00232180] | Phase 3 | 2,743 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| The Effects of Eplerenone on Left Ventricular Remodelling Post-Acute Myocardial Infarction: a Double-Blind Placebo-Controlled Cardiac MR-Based Study[NCT00132093] | Phase 4 | 100 participants | Interventional | 2005-04-30 | Completed | ||
| A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction[NCT01176968] | Phase 4 | 1,012 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction[NCT01624883] | 18,000 participants (Actual) | Observational | 2012-04-30 | Completed | |||
| Aldosterone Lethal Effects Blocked in AMI Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up: THE ALBATROSS TRIAL[NCT01059136] | Phase 3 | 1,603 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Baseline Characteristics, Processes of Care, System-related Factors, and Clinical Outcomes Associated With the Quality and Safety of Initial Management for ST-segment Elevation Myocardial Infarction: A Multicenter Cohort Study[NCT02788344] | 6,920 participants (Actual) | Observational | 2017-05-15 | Completed | |||
| MINeralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (STEMI)[NCT01882179] | Phase 3 | 61 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA Study.[NCT00725738] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2008-05-31 | Recruiting | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Eplerenone for Central Serous Chorioretinopathy: A Pilot Study[NCT01822561] | Phase 2 | 17 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| Usability and Utility Assessment of Passive Remote Monitoring of Multiple Novel Indicators of Heart Failure[NCT04267744] | 165 participants (Anticipated) | Interventional | 2020-02-11 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 288 |
| Placebo: Double-blind Phase | 392 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 249 |
| Placebo: Double-blind Phase | 356 |
Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 408 | 463 |
| Placebo: Double-blind Phase | 491 | 552 |
Death due to any cause. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 171 | 205 |
| Placebo: Double-blind Phase | 213 | 253 |
Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 462 | 530 |
| Placebo: Double-blind Phase | 569 | 636 |
Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 270 | 311 |
| Placebo: Double-blind Phase | 376 | 418 |
First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 304 | 346 |
| Placebo: Double-blind Phase | 399 | 439 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 147 | 178 |
| Placebo: Double-blind Phase | 185 | 215 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 45 | 49 |
| Placebo: Double-blind Phase | 33 | 40 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 21 | 24 |
| Placebo: Double-blind Phase | 26 | 31 |
First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 164 | 186 |
| Placebo: Double-blind Phase | 253 | 277 |
Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 170 | 194 |
| Placebo: Double-blind Phase | 262 | 287 |
First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (>) 5.5 milliequivalents per liter (mEq/L). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 4 | 4 |
| Placebo: Double-blind Phase | 3 | 3 |
First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 9 | 10 |
| Placebo: Double-blind Phase | 8 | 10 |
First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 61 | 76 |
| Placebo: Double-blind Phase | 59 | 78 |
First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 33 | 45 |
| Placebo: Double-blind Phase | 41 | 53 |
New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 950, 937) | Up to 59.5 months (complete DB) (n= 956, 940) | |
| Eplerenone: Double-blind Phase | 32 | 41 |
| Placebo: Double-blind Phase | 52 | 59 |
The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 904, 973) | Up to 59.5 months (complete DB) (n= 907, 975) | |
| Eplerenone: Double-blind Phase | 34 | 42 |
| Placebo: Double-blind Phase | 40 | 47 |
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
The occurrence of first occurrence of BNP >200 pg/mL or NT-proBNP >450, >900 or >1800 pg/mL for ages <50 years, 50 to 75 years and >75 years, respectively (recorded 28 days or later post-randomization). Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 81 |
| Placebo Plus Standard of Care | 131 |
The occurrence of cardiovascular mortality from randomization. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 2 |
| Placebo Plus Standard of Care | 2 |
Change in serum level of ICTP at 6 months post-randomization. The continuous endpoint was assessed using ANCOVA model, fitted with corresponding baseline and treatment. It was analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | μg/L (Median) |
|---|---|
| Eplerenone Plus Standard of Care | 3.70 |
| Placebo Plus Standard of Care | 3.70 |
Change in serum level of Interleukin-6 at 6 months post-randomization. The continuous endpoint was assessed using ANCOVA model, fitted with corresponding baseline and treatment. It was analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | pg/mL (Median) |
|---|---|
| Eplerenone Plus Standard of Care | 1.845 |
| Placebo Plus Standard of Care | 1.755 |
The decision to provide an ICD or CRT. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 3 |
| Placebo Plus Standard of Care | 3 |
The occurrence of first diagnosis of heart failure from the date of randomization. Time-to-event analyses were measured from the date of randomization, and a subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 7 |
| Placebo Plus Standard of Care | 11 |
Electrocardiogram Q wave to the end of the S wave corresponding to ventricle depolarization (QRS) duration at 6 months post-randomization. The continuous endpoints were assessed using analysis of covariance (ANCOVA) model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on last observation carried forward (LOCF) and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | Milliseconds (msec) (Mean) |
|---|---|
| Eplerenone Plus Standard of Care | 93.31 |
| Placebo Plus Standard of Care | 94.62 |
The occurrence of first and each subsequent episode (after an event-free interval of ≥ 48 hours) of sustained ventricular tachycardia or ventricular fibrillation. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 0 |
| Placebo Plus Standard of Care | 0 |
Cardiovascular mortality is defined as any mortality adjudicated as death due to sudden cardiac death, myocardial infarction (MI), worsening heart failure, cardiac arrhythmia, other cause (such as pulmonary embolism, peripheral arterial disease [PAD], etc.). Hospitalization due to congestive heart failure (CHF) and requires extended hospital stay or frequent visits to emergency room, observation unit or in-patient care, due to CHF as the primary or secondary diagnosis supported by a discharge report or clinical summary for hospitalization as determined by the endpoint adjudication committee (EAC). A composite of time to first event of cardiovascular mortality (CV), re-hospitalization or extended initial hospital stay due to diagnosis of heart failure, sustained ventricular tachycardia or fibrillation, ejection fraction ≤40% after 1 month or BNP >200 pg/mL or NT-proBNP >450 pg/mL (age <50 years); >900 pg/mL (age 50 to 75 years) or >1800 pg/mL (age >75 years) after 1 month. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 92 |
| Placebo Plus Standard of Care | 149 |
The occurrence of first recorded EF ≤40% (recorded 28 days or later post-randomization). Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 20 |
| Placebo Plus Standard of Care | 19 |
The occurrence of second or subsequent nonfatal MI. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Events (Number) |
|---|---|
| Eplerenone Plus Standard of Care | 10 |
| Placebo Plus Standard of Care | 6 |
Change in serum levels of aldosterone and cortisol at 6 months post-randomization. The continuous endpoints were assessed using ANCOVA model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | nmol/L (Median) | |
|---|---|---|
| Aldosterone | Serum Cortisol | |
| Eplerenone Plus Standard of Care | 0.355 | 379.0 |
| Placebo Plus Standard of Care | 0.210 | 366.0 |
Change in serum levels of PIIINP, Galectin 3, and PINP at 6 months post-randomization. The continuous endpoints were assessed using ANCOVA model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months
| Intervention | ng/mL (Median) | ||
|---|---|---|---|
| PIIINP | Galectin 3 | PINP | |
| Eplerenone Plus Standard of Care | 4.20 | 11.20 | 30.0 |
| Placebo Plus Standard of Care | 4.30 | 10.60 | 32.0 |
LAD recorded each time an echocardiogram is conducted. The continuous endpoints were assessed using ANCOVA model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 0-24 months
| Intervention | Centimeters (cm) (Mean) | |
|---|---|---|
| Month 6 (N = 268, 243) | Final Visit (N = 393, 378) | |
| Eplerenone Plus Standard of Care | 3.92 | 3.91 |
| Placebo Plus Standard of Care | 3.90 | 3.87 |
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
Visual acuity will be measured with standard eye charts, with manifest refraction at the initiation and conclusion of treatment. Although an important measure, this was not chosen as the primary outcome measure, as some patients with central serous chorioretinopathy may have a normal visual acuity when properly refracted (refraction can change with elevation of the macula by sub-retinal fluid) (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | logMAR (Mean) |
|---|---|
| Patients That Took Eplerenone | -0.03 |
Automated software to calculate the thickness of the macula is standard on commercial OCT devices. Macular thickness before and after treatment will be assessed and compared. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | Microns (Mean) |
|---|---|
| Patients That Received Eplerenone | -26 |
Eplerenone can cause elevation of serum potassium. After initial screening, serum potassium was evaluated at 1 and 4 weeks after baseline. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | mEq/L (Mean) |
|---|---|
| Patients That Received Eplerenone | 0.11 |
Choroidal thickness can be measured using optical coherence tomography, and is known to be affected in patients with central serous chorioretinopathy. Thickness of the choroid under the fovea will be manually calculated in both the study eye. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | microns (Mean) |
|---|---|
| Patients That Received Eplerenone | 29.8 |
Optical coherence tomography is an imaging technique capable of extremely high resolution (~5-7 microns) imaging of the macula, and is able to detect the presence and amount of subretinal fluid present, the key anatomic abnormality in Central Serous Chorioretinopathy (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | participants (Number) |
|---|---|
| Patients That Took Eplerenone | 0 |
27 reviews available for spironolactone and Myocardial Infarction
| Article | Year |
|---|---|
A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
Topics: Bayes Theorem; Clinical Trials as Topic; Cost-Benefit Analysis; Eplerenone; Heart Failure; Humans; M | 2010 |
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic | 2010 |
Review article: eplerenone: an underused medication?
Topics: Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hyperkalemia; Hypertension; Hypertrophy, | 2010 |
Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
Topics: Diuretics; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spiron | 2002 |
Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?
Topics: Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Contro | 2003 |
NEUROGENIC MULTIFOCAL DESTRUCTION OF MYOCARDIAL TISSUE (PATHOGENIC MECHANISM AND ITS PREVENTION).
Topics: Adrenal Cortex Hormones; Catecholamines; Epinephrine; Heart Diseases; Hypoxia; Myocardial Infarction | 1963 |
Aldosterone blockade in patients with systolic left ventricular dysfunction.
Topics: Aldosterone; Eplerenone; Forecasting; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Mal | 2003 |
[Significance of aldosterone antagonist therapy].
Topics: Aldosterone; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dr | 2004 |
Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Digoxin; Enzyme Inhibitors; Eplerenone; Female; Human | 2004 |
Aldosterone target organ protection by eplerenone.
Topics: Aldosterone; Blood Vessels; Brain; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hype | 2004 |
Role of the selective aldosterone receptor blockers in arterial hypertension.
Topics: Animals; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarc | 2004 |
Eplerenone in the treatment of chronic heart failure.
Topics: Aldosterone; Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineraloc | 2004 |
Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Recep | 2004 |
Integrating traditional and emerging treatment options in heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biological Availability; Eplerenone; Half-Life; Huma | 2004 |
Eplerenone: will it have a role in the treatment of acute coronary syndromes?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Collagen; Coronary Restenosis; Eplerenone; Humans; | 2004 |
Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Enalapril; Eplerenone; Heart Fa | 2004 |
Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Eplerenone; Mineraloc | 2004 |
Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction.
Topics: Adolescent; Adult; Aged; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recepto | 2004 |
Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
Topics: Animals; Area Under Curve; Economics, Pharmaceutical; Eplerenone; Half-Life; Heart Failure; Humans; | 2004 |
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2004 |
A new selective aldosterone antagonist. Inspra's role in hypertension and post-MI heart failure.
Topics: Arrhythmias, Cardiac; Drug Interactions; Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; | 2005 |
[Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diu | 2006 |
Aldosterone blockade in post-acute myocardial infarction heart failure.
Topics: Algorithms; Cardiac Output, Low; Eplerenone; Humans; Hyperkalemia; Hypotension; Mineralocorticoid Re | 2006 |
Eplerenone after myocardial infarction?
Topics: Contraindications; Drug Costs; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardia | 2008 |
Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
Topics: Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor | 2007 |
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
Topics: Aldosterone; Animals; Cardiovascular System; Clinical Trials as Topic; Endothelium, Vascular; Eplere | 2001 |
[Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; A | 2001 |
50 trials available for spironolactone and Myocardial Infarction
| Article | Year |
|---|---|
Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.
Topics: Heart Failure; Humans; Magnesium; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pro | 2022 |
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Double | 2020 |
Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Creatinine; Diabetes Mellitus; Disease Progress | 2021 |
Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
Topics: Aged; Cause of Death; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Miner | 2017 |
Galectin-3 and cardiac function in survivors of acute myocardial infarction.
Topics: Aged; Eplerenone; Extracellular Matrix; Female; Galectin 3; Humans; Magnetic Resonance Imaging; Male | 2013 |
Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s
Topics: Aged; Arterial Pressure; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorti | 2014 |
Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
Topics: Aged; Aged, 80 and over; Comorbidity; Double-Blind Method; Eplerenone; Female; Humans; Male; Middle | 2014 |
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Length of Stay; Male; Middle Aged; M | 2014 |
Mineralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-elevation myocardial infarction (the MINIMISE STEMI Trial): rationale and study design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Electrocardiography; Humans; Magnet | 2015 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Topics: Age Factors; Aged; Canrenoic Acid; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up | 2016 |
Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac
Topics: Aged; Biomarkers; Endothelin-1; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; | 2017 |
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
Topics: Aged; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch | 2008 |
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Hyperkalemia; Incidence; Logistic Models; Male; Min | 2008 |
Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
Topics: Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Eplerenone; Health Care Costs; Heart F | 2008 |
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
Topics: Acute Disease; Aged; Cohort Studies; Eplerenone; Female; Follow-Up Studies; Health Care Costs; Healt | 2009 |
Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction.
Topics: Female; Humans; Incidence; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Inf | 2009 |
Plasma apelin concentration is depressed following acute myocardial infarction in man.
Topics: Apelin; Biomarkers; Chromatography, High Pressure Liquid; Double-Blind Method; Echocardiography; Epl | 2009 |
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP
Topics: Aged; Biomarkers; Collagen Type I; Collagen Type III; Death, Sudden, Cardiac; Eplerenone; Extracellu | 2009 |
A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction.
Topics: Aged; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hypertension; | 2009 |
Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study).
Topics: Aged; Electrocardiography, Ambulatory; Eplerenone; Female; Heart Failure; Heart Rate; Humans; Male; | 2009 |
Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Magnetic Resonance Imaging; Male; | 2009 |
Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction.
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Male; Matrix Metalloproteinases; | 2010 |
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Topics: Aged; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Length of Sta | 2009 |
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
Topics: Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Hum | 2009 |
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.
Topics: Aged; Biomarkers; Cohort Studies; Double-Blind Method; Eplerenone; Female; Humans; Interleukin-1 Rec | 2010 |
Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction.
Topics: Chi-Square Distribution; Contrast Media; Double-Blind Method; Eplerenone; Female; Gadolinium DTPA; H | 2010 |
The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction: a randomized follow-up study.
Topics: Aged; Angioplasty, Balloon, Coronary; Atrial Function; Chi-Square Distribution; Echocardiography, Do | 2010 |
Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty; Autonomic Nervous System Diseases; Collagen Type III; Double-Blind Method; Female | 2011 |
Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
Topics: Aldosterone; Biomarkers; Double-Blind Method; Echocardiography; Electrocardiography; Eplerenone; Fem | 2011 |
Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
Topics: Aged; Eplerenone; Glomerular Filtration Rate; Heart Failure; Heart Failure, Systolic; Humans; Kidney | 2012 |
Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS.
Topics: Aged; Blood Glucose; Diabetes Complications; Double-Blind Method; Eplerenone; Female; Humans; Hyperg | 2012 |
Interleukin-21--a biomarker of importance in predicting myocardial function following acute infarction?
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Interleukins; Male; Matrix Metall | 2012 |
Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial.
Topics: Acute Disease; Aged; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Heart Failu | 2013 |
Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction?
Topics: Adult; Aged; Analysis of Variance; Chi-Square Distribution; Dose-Response Relationship, Drug; Echoca | 2013 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure | 2003 |
Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial in
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Collagen; Drug Th | 2003 |
Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION.
Topics: Aged; Defibrillators, Implantable; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Min | 2003 |
[Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS].
Topics: Acute Disease; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Eple | 2003 |
[Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial i
Topics: Biomarkers; Collagen; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocard | 2004 |
Prognostic value of health status in patients with heart failure after acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Americas; Cardiovascular Diseases; Cohort Studies; Comorbidity; Dise | 2004 |
Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction.
Topics: Adolescent; Adult; Aged; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Recepto | 2004 |
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Topics: Aged; Cause of Death; Comorbidity; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Eplerenon | 2005 |
RALES, EPHESUS and redox.
Topics: Aldosterone; Animals; Heart Failure; Humans; Inflammation; Mineralocorticoid Receptor Antagonists; M | 2005 |
[Effect of spironolactone on left ventricular remodeling in patients with acute myocardial infarction].
Topics: Female; Humans; Male; Myocardial Infarction; Myocardial Revascularization; Natriuretic Peptide, Brai | 2005 |
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
Topics: Aged; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrati | 2005 |
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction
Topics: Adult; Aged; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Sp | 2006 |
Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
Topics: Adult; Aged; Cost-Benefit Analysis; Eplerenone; Female; Health Care Costs; Humans; Male; Middle Aged | 2006 |
[Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation].
Topics: Acute Disease; Adult; Aged; Anti-Arrhythmia Agents; Canrenoic Acid; Clinical Trials as Topic; Female | 1984 |
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Disease-Free Survival; Double-Blind | 1997 |
Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study).
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Disease Progression; Eplerenone; Health Status Indic | 2002 |
139 other studies available for spironolactone and Myocardial Infarction
| Article | Year |
|---|---|
INFLUENCE OF COMPLEX TREATMENT WITH MAGNESIUM AND POTASSIUM SALTS OF GLUCONIC ACID, EPLERENONE AND RIVAROXABAN ON DYNAMICS OF INDICATORS OF ISCHEMIA AND MYOCARDIAL REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE AFTER MYOCARDIAL INFARCTION.
Topics: Eplerenone; Gluconates; Heart Failure; Humans; Magnesium; Mineralocorticoid Receptor Antagonists; My | 2021 |
Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2022 |
The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat.
Topics: Animals; Antifibrotic Agents; Cytochrome P-450 CYP1A1; Disease Progression; Fibrosis; Heart; Hyperte | 2021 |
Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10-year follow-up of the Eplerenone Remodelling in Myocardial Infarction without Heart Failure trial.
Topics: Biomarkers; Eplerenone; Follow-Up Studies; Heart Failure; Humans; Magnetic Resonance Spectroscopy; M | 2022 |
Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction.
Topics: Animals; Heart Failure; Humans; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; | 2022 |
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Sp | 2022 |
Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.
Topics: Collagen Type I; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardi | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, A | 2020 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure.
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineral | 2018 |
Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Female; Heart Failure; Humans; Hyperkalemia; Male; | 2018 |
Use of Nitrates and Risk of Cardiovascular Events in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarc | 2019 |
Statins in heart failure: not yet the end of the story?
Topics: Female; Heart Failure, Systolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Miner | 2013 |
Systematic approach: an evidence management strategy for better decision-making.
Topics: Decision Making; Eplerenone; Evidence-Based Medicine; Humans; Mineralocorticoid Receptor Antagonists | 2013 |
Letter by Januzzi regarding article, "galectin-3 and cardiac function in survivors of acute myocardial infarction".
Topics: Female; Galectin 3; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spi | 2013 |
Response to Letter Regarding Article, “Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction”.
Topics: Female; Galectin 3; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spi | 2013 |
Mechanisms involved in the beneficial effects of spironolactone after myocardial infarction.
Topics: Analysis of Variance; Animals; Blotting, Western; Body Weights and Measures; Collagen; Echocardiogra | 2013 |
[REMINDER Study: myocardial infarct without heart failure: does eplerenone have an advantage?].
Topics: Double-Blind Method; Early Medical Intervention; Eplerenone; Germany; Heart Failure; Humans; Mineral | 2013 |
Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Thrombos | 2014 |
Evaluating the efficacy of mineralocorticoid receptor antagonism in patients with STEMI without heart failure.
Topics: Eplerenone; Female; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spi | 2014 |
Acute coronary syndromes: Treatment for low-risk patients with STEMI--challenges remain.
Topics: Female; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2014 |
Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade.
Topics: Aldosterone; Animals; Apoptosis; Caspase 3; Disease Models, Animal; Eplerenone; Macrophages; Male; M | 2014 |
Spironolactone lowers the rate of repeat revascularization in acute myocardial infarction patients treated with percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Comorbidity; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor | 2014 |
Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling.
Topics: Acute Kidney Injury; Animals; Galectin 3; Heart Failure; Interleukins; Male; Myocardial Infarction; | 2015 |
Spironolactone Regulates HCN Protein Expression Through Micro-RNA-1 in Rats With Myocardial Infarction.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Gene Expression Regulation; Hyperpolarization | 2015 |
National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011.
Topics: Aged; China; Female; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagoni | 2015 |
Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Databases, Factual; Drug Prescriptions; D | 2016 |
MRAs in Patients With AMI Without Early Evidence of Heart Failure: Time for Reappraisal?
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2016 |
The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction.
Topics: Actinin; Animals; Atrial Natriuretic Factor; Blotting, Western; Eplerenone; Fibrosis; Gene Expressio | 2016 |
Mineralocorticoid Receptor Antagonism in Acute Myocardial Infarction: Who Benefits?
Topics: Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Receptors, Mineralocorticoid; | 2016 |
Reply: Mineralocorticoid Receptor Antagonism in Acute Myocardial Infarction: Who Benefits?
Topics: Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Receptors, Mineralocorticoid; | 2016 |
Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery.
Topics: Animals; Heart Aneurysm; Heart Ventricles; Hemodynamics; Lung; Male; Mineralocorticoid Receptor Anta | 2008 |
[Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart].
Topics: Drug Administration Schedule; Emergencies; Eplerenone; Heart Failure; Humans; Mineralocorticoid Rece | 2008 |
Eplerenone in patients with acute myocardial infarction complicated by heart failure.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial | 2008 |
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri | 2009 |
[A mourning case that referred with sexual identity disorder secondary to a general medical condition].
Topics: Bereavement; Depression; Digoxin; Erectile Dysfunction; Female; Gender Identity; Gynecomastia; Human | 2009 |
Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction.
Topics: Aldosterone; Angina, Unstable; Animals; Apoptosis; Dexamethasone; Glucocorticoids; Hormone Antagonis | 2009 |
Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion.
Topics: Animals; Canrenoic Acid; Eplerenone; Ischemic Preconditioning, Myocardial; Mice; Mice, Knockout; Min | 2010 |
Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.
Topics: Animals; Cluster Analysis; Eplerenone; Female; Fibrosis; Gene Expression Profiling; Gene Expression | 2009 |
Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cost-Benefit Analysis; | 2010 |
Aldosterone receptor antagonists: effective but often forgotten.
Topics: Eplerenone; Female; Follow-Up Studies; Humans; Hypertension; Middle Aged; Mineralocorticoid Receptor | 2010 |
Monocyte chemoattractant protein-1: a dichotomous role in cardiac remodeling following acute myocardial infarction in man?
Topics: Biomarkers; Chemokine CCL2; Cohort Studies; Contrast Media; Eplerenone; Female; Humans; Magnetic Res | 2010 |
[Application of cardiac resynchronization therapy and ivabradine in a patient with chronic heart failure].
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiova | 2010 |
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa | 2010 |
Timing of defibrillator implant after acute myocardial infarction: what's new?
Topics: Death, Sudden, Cardiac; Defibrillators, Implantable; Eplerenone; Health Knowledge, Attitudes, Practi | 2011 |
Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin-Converting Enzyme | 2011 |
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure.
Topics: Aged; Diabetic Angiopathies; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineraloc | 2011 |
Prognostic value of plasma renin activity in heart failure.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bioma | 2011 |
[The EMPHASIS-HF study].
Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinic | 2011 |
[Pharmacological sheet: eplerenone (Inspra), orally].
Topics: Cardiovascular Diseases; Drug Interactions; Eplerenone; Humans; Mineralocorticoid Receptor Antagonis | 2011 |
The number of leads with fragmented QRS is independently associated with cardiac death or hospitalization for heart failure in patients with prior myocardial infarction.
Topics: Age Factors; Aged; Electrocardiography; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier | 2012 |
Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure.
Topics: Aldosterone; Animals; Cell Proliferation; Echocardiography; Heart Failure; Hypertension, Pulmonary; | 2011 |
Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model of chronic cardiorenal syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardio-Renal Syndrome; Gene Expression; Imidazoles | 2012 |
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Eplerenone; Heart; Heart Failure; Ho | 2012 |
Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Caspase 2; Caspase 3; Caspase 9; Cell Line; Dose- | 2012 |
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel | 2012 |
Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone.
Topics: Aged; Biomarkers; Enzyme-Linked Immunosorbent Assay; Eplerenone; Female; Humans; Male; Matrix Metall | 2012 |
New treatments for myocardial fibrosis.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Canrenone; Clinical Trials as Topic; | 2002 |
Aldosterone blockade and heart failure.
Topics: Aldosterone; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial I | 2003 |
More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Recep | 2003 |
Aldosterone blockade in patients with acute myocardial infarction.
Topics: Acute Disease; Catecholamines; Collagen; Eplerenone; Heart Rate; Humans; Mineralocorticoid Receptor | 2003 |
Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blotting, Western; Drug Therapy, Combinati | 2003 |
Eplerenone in patients with left ventricular dysfunction.
Topics: Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Research Design; | 2003 |
Eplerenone in patients with left ventricular dysfunction.
Topics: Death, Sudden, Cardiac; Eplerenone; Humans; Hypokalemia; Mineralocorticoid Receptor Antagonists; Myo | 2003 |
Eplerenone in patients with left ventricular dysfunction.
Topics: Contraindications; Creatinine; Eplerenone; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagoni | 2003 |
Potential antiapoptotic activity of aldosterone antagonists in postinfarction remodeling.
Topics: Animals; Apoptosis; Disease Models, Animal; Dogs; Mineralocorticoid Receptor Antagonists; Myocardial | 2003 |
Aldosterone blockade after myocardial infarction.
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid | 2003 |
[Pressure of the tissues in various post-infarct complications and under the influence of aldosterone, spirolactone and saline administration].
Topics: Aldosterone; Heart Failure; Humans; Myocardial Infarction; Sodium Chloride; Spironolactone | 1962 |
Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats.
Topics: Animals; Cicatrix; Collagen; Hydralazine; Losartan; Male; Myocardial Infarction; Myocardium; Organ S | 2003 |
Two better than one.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Class Ib Phosphatidylinositol 3-Kina | 2003 |
Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blotting, Western; Drug Synergism; Drug Therapy, | 2003 |
Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.
Topics: Action Potentials; Animals; Cardiotonic Agents; Coronary Circulation; Drug Therapy, Combination; Ele | 2003 |
[Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
Topics: Controlled Clinical Trials as Topic; Death, Sudden, Cardiac; Diuretics; Double-Blind Method; Epleren | 2003 |
Role of a selective aldosterone blocker in mice with chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output; Collagen; Disease Models, Animal; | 2004 |
The European Society of Cardiology working group on heart failure: Heart Failure Update 2003.
Topics: Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Eplerenone; Europe; Heart Failure; Humans; Metop | 2003 |
Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction.
Topics: Animals; Atrial Natriuretic Factor; Benzimidazoles; Biphenyl Compounds; Collagen Type I; Collagen Ty | 2004 |
Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction.
Topics: Action Potentials; Animals; Aorta, Abdominal; Aortic Valve Stenosis; Calcium; Calcium Channels, L-Ty | 2004 |
Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction.
Topics: Analysis of Variance; Animals; Aorta; Diastole; Echocardiography; Eplerenone; Hemodynamics; Kidney; | 2004 |
Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats.
Topics: Administration, Oral; Aldosterone; Animals; Central Nervous System; Collagen; Epinephrine; Injection | 2004 |
[Therapy of heart failure after myocardial infarction. With eplerenone a new course].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Comb | 2004 |
[More benefit in hypertension and high-grade reduction of the pump performance. Earlier beginning of therapy maximizes the benefit].
Topics: Controlled Clinical Trials as Topic; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Min | 2004 |
Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI.
Topics: Amiloride; Animals; Baroreflex; Blood Pressure; Epithelial Sodium Channels; Male; Mineralocorticoid | 2005 |
Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Sp | 2005 |
Implantable cardioverter-defibrillator therapy after myocardial infarction.
Topics: Arrhythmias, Cardiac; Defibrillators, Implantable; Eplerenone; Humans; Mineralocorticoid Receptor An | 2005 |
[Aldosterone and aldosterone antagonists. Eplerenone in cardiac insufficiency after myocardial infarction].
Topics: Aldosterone; Cardiac Output, Low; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocar | 2005 |
Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction.
Topics: Animals; Blood Pressure; Blotting, Northern; Body Weight; Coronary Vessels; Echocardiography, Dopple | 2005 |
Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction.
Topics: Aldosterone; Animals; Cytochrome P-450 CYP11B2; Gene Expression Regulation; Male; Mice; Mice, Knocko | 2005 |
Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, Western; Collagen Ty | 2005 |
Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen.
Topics: Aldosterone; Angiotensinogen; Animals; Animals, Genetically Modified; Brain; Cell Size; Fibronectins | 2005 |
[Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
[Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Hu | 2005 |
Letter regarding article by Weintraub et al, "Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure".
Topics: Cost-Benefit Analysis; Drug Costs; Eplerenone; Health Care Costs; Humans; Myocardial Infarction; Pla | 2005 |
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Atria; Heart Failure; Male; M | 2005 |
Heart failure after acute ST-segment elevation myocardial infarction: what should we do about it?
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pa | 2005 |
Sudden death in patients with myocardial infarction.
Topics: Death, Sudden, Cardiac; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; M | 2005 |
Expression of procollagen C-proteinase enhancer-1 in the remodeling rat heart is stimulated by aldosterone.
Topics: Aldosterone; Animals; Body Weight; Collagen Type I; Glycoproteins; Heart; In Situ Hybridization; Int | 2006 |
[Heart failure after myocardial infarction. Increased risk, poorer treatment].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Eplerenone; Heart Failure; Hospital Mortality; | 2005 |
[Efficient improvement of prognosis after myocardial infarct? Additional aldosterone inhibition is required].
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Epler | 2005 |
Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
Topics: Aldosterone; Animals; Cardiotonic Agents; Drug Interactions; Eplerenone; Heart; Hemodynamics; In Vit | 2006 |
Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Topics: Clinical Trials as Topic; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial | 2006 |
[Combination drug therapy after myocardial infarction. Early aldosterone blocking protects risk patients].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; D | 2006 |
[Cardioverter-defibrillator (ICD) and resynchronization in every patient with cardiac failure].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2006 |
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis; | 2006 |
Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Chronic | 2007 |
Primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Eplerenone; Humans; Mineralocorticoid Receptor Antagoni | 2007 |
Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone.
Topics: Attitude to Health; Cost-Benefit Analysis; Eplerenone; Female; Financing, Personal; Focus Groups; He | 2008 |
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Eplerenone; Female; Heart Failure; Humans; H | 2008 |
[Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study].
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; | 2007 |
Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Animals; Apoptosis; Blood Pressure; Cells, Cultured; Fi | 2007 |
[Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction].
Topics: Acute Disease; Adult; Aged; Cause of Death; Comorbidity; Female; Follow-Up Studies; Heart Failure; H | 2006 |
Brain mechanisms contributing to sympathetic hyperactivity and heart failure.
Topics: Angiotensinogen; Animals; Animals, Genetically Modified; Gene Transfer Techniques; Heart Failure; In | 2007 |
Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction.
Topics: Animals; Aorta, Thoracic; Disease Models, Animal; Dose-Response Relationship, Drug; Eplerenone; Male | 2007 |
Avoiding vicious circles: mineralocorticoid receptor antagonism prevents vascular oxidative stress early after myocardial infarction.
Topics: Aldosterone; Angiotensin II; Animals; Endothelium, Vascular; Eplerenone; Humans; Mice; Mineralocorti | 2007 |
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Topics: Aldosterone; Animals; Clodronic Acid; Collagen; Cytokines; Eplerenone; Factor XIIIa; Heart Failure; | 2008 |
[Debatable questions of strophanthin and spironolactone treatment in certain forms of acute myocardial infarct].
Topics: Adult; Animals; Drug Evaluation; Drug Evaluation, Preclinical; Female; Heart Rate; Hemodynamics; Hum | 1980 |
Precision of digoxin radioimmunoassays and matrix effects: four kits compared.
Topics: Digoxin; False Positive Reactions; Humans; Hypertension; Myocardial Infarction; Radioimmunoassay; Re | 1981 |
Left ventricular dysfunction: causes, natural history, and hopes for reversal.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Coronary Disease; | 2000 |
Effect of a selective aldosterone receptor antagonist in myocardial infarction.
Topics: Animals; Eplerenone; Fibrosis; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; | 2001 |
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Anta | 2001 |
Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure.
Topics: Animals; Baroreflex; Blood Pressure; Drinking; Heart; Heart Failure; Male; Mineralocorticoid Recepto | 2001 |
Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Chronic Disease; Disease Mo | 2001 |
Effect of treatment of hypertension in the primary preventive trial, Göteborg, Sweden.
Topics: Adrenergic beta-Antagonists; Bethanidine; Cardiovascular Diseases; Cerebrovascular Disorders; Corona | 1979 |
Raised serum lipid concentrations during diuretic treatment of hypertension: a study of predictive indexes.
Topics: Adult; Cholesterol; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; | 1978 |
[New aspects of treatment of hemodynamic complications in acute myocardial infarction (author's transl)].
Topics: Animals; Canrenoic Acid; Digitalis Glycosides; Dogs; Dopamine; Furosemide; Hemodynamics; Humans; Myo | 1977 |
[Disorder of the mineralocorticoid function of the adrenals in the acute period of myocardial infarct and the ways for its correction].
Topics: Acute Disease; Adrenal Gland Diseases; Adult; Aged; Aldosterone; Chronic Disease; Coronary Disease; | 1979 |
Opposing effects of deoxycorticosterone and spironolactone on isoprenaline-induced myocardial infarction.
Topics: Animals; Body Weight; Corticosterone; Desoxycorticosterone; Isoproterenol; Lipids; Male; Myocardial | 1979 |
[Aldosterone antagonists in coronary insufficiency].
Topics: Arrhythmias, Cardiac; Canrenoic Acid; Heart Failure; Humans; Myocardial Contraction; Myocardial Infa | 1978 |
Prevention of various forms of metabolic myocardial necrosis by catatoxic steroids.
Topics: Animals; Cardiomyopathies; Desoxycorticosterone; Digitoxin; Disease Models, Animal; Ethylestrenol; F | 1970 |
Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Digital | 1972 |
[Proceedings: Effect of potassium canrenoate (aldactone pro inj.) and digoxin on hemodynamics and infarct size in experimental myocardial infarct].
Topics: Animals; Blood Pressure; Cardiac Output; Digoxin; Dogs; Electrocardiography; Myocardial Infarction; | 1974 |
Heart failure and cardiac arrhythmias.
Topics: Arrhythmia, Sinus; Arrhythmias, Cardiac; Coronary Disease; Digoxin; Diuretics; Electroconvulsive The | 1974 |
Drug therapy in cardiogenic shock.
Topics: Cardiac Output; Digitalis Glycosides; Dopamine; Glucagon; Hemodynamics; Humans; Isoproterenol; Metap | 1973 |
Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.
Topics: Adult; Aged; Carboxylic Acids; Female; Fluorometry; Half-Life; Heart Failure; Humans; Ketosteroids; | 1974 |
Chemical prevention of myocardial necrosis.
Topics: Adrenal Cortex Hormones; Animals; Diet Therapy; Heart Transplantation; Humans; Myocardial Infarction | 1970 |
Role of aldosterone in myocardial infarction.
Topics: Adult; Aldosterone; Animals; Chromatography; Diet, Sodium-Restricted; Dogs; Humans; Male; Myocardial | 1965 |
Digitoxin induced cardiac necrosis and its inhibition.
Topics: Animals; Cardiomyopathies; Digitoxin; Drug Synergism; Enzyme Induction; Female; Heart; Injections, S | 1969 |
[Acid-base equilibrium and blood gas analysis in clinical cardiology].
Topics: Acetazolamide; Acid-Base Equilibrium; Bicarbonates; Blood Gas Analysis; Body Weight; Diagnosis, Diff | 1970 |
[Effect of aldactone-A on electrolyte excretion in patients with myocardial infarcts].
Topics: Aged; Calcium; Diuretics; Female; Humans; Magnesium; Male; Middle Aged; Myocardial Infarction; Sodiu | 1968 |
[Mineral-corticoid activity of licorice].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Glycyrrhiza; Humans; Male; Middle Aged; Myocardial Infar | 1965 |